IN2014MN02418A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02418A
IN2014MN02418A IN2418MUN2014A IN2014MN02418A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A IN 2418MUN2014 A IN2418MUN2014 A IN 2418MUN2014A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A
Authority
IN
India
Prior art keywords
methods
breast cancer
subject
gene expression
evaluating
Prior art date
Application number
Other languages
English (en)
Inventor
Sean M Ferree
James Justin Storhoff
Joel S Parker
Charles M Perou
Matthew J Ellis
Philip S Bernard
Torsten O Nielsen
Original Assignee
Nanostring Technologies Inc
Univ North Carolina
Univ Utah Res Found
British Columbia Cancer Agency
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanostring Technologies Inc, Univ North Carolina, Univ Utah Res Found, British Columbia Cancer Agency, Univ Washington filed Critical Nanostring Technologies Inc
Publication of IN2014MN02418A publication Critical patent/IN2014MN02418A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN2418MUN2014 2012-05-22 2013-05-22 IN2014MN02418A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650209P 2012-05-22 2012-05-22
US201361753673P 2013-01-17 2013-01-17
PCT/US2013/042157 WO2013177245A2 (en) 2012-05-22 2013-05-22 Nano46 genes and methods to predict breast cancer outcome

Publications (1)

Publication Number Publication Date
IN2014MN02418A true IN2014MN02418A (ko) 2015-08-14

Family

ID=49624503

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2418MUN2014 IN2014MN02418A (ko) 2012-05-22 2013-05-22

Country Status (12)

Country Link
US (3) US20130337444A1 (ko)
EP (1) EP2852689B1 (ko)
JP (1) JP6325530B2 (ko)
CN (2) CN111500718A (ko)
AU (1) AU2013266419B2 (ko)
BR (1) BR112014029300A2 (ko)
CA (1) CA2874492C (ko)
ES (1) ES2763931T3 (ko)
IL (1) IL235795B (ko)
IN (1) IN2014MN02418A (ko)
MX (1) MX369628B (ko)
WO (1) WO2013177245A2 (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158143A1 (en) 2008-05-30 2009-12-30 The University Of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
JP5971769B2 (ja) 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル アントラサイクリン療法を用いて乳癌を処置する方法
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
EP2997163A4 (en) * 2013-05-13 2017-02-22 Nanostring Technologies, Inc Methods to predict risk of recurrence in node-positive early breast cancer
EP3013983B1 (en) 2013-06-25 2023-02-15 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
WO2015035377A1 (en) * 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
CN107208144B (zh) 2014-11-21 2021-06-08 纳米线科技公司 无酶且无扩增的测序
US10246700B2 (en) * 2014-11-24 2019-04-02 Nanostring Technologies, Inc. Methods and apparatuses for gene purification and imaging
JP2018500895A (ja) * 2014-12-09 2018-01-18 キングス・カレッジ・ロンドン タキサン療法による乳癌治療
SG11201707515SA (en) 2015-04-10 2017-10-30 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US20180209981A1 (en) * 2015-07-23 2018-07-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
CA3023566A1 (en) 2016-05-16 2017-11-23 Nanostring Technologies, Inc. Methods for detecting target nucleic acids in a sample
US11352667B2 (en) 2016-06-21 2022-06-07 10X Genomics, Inc. Nucleic acid sequencing
WO2018074865A2 (ko) * 2016-10-21 2018-04-26 서울대학교병원 유방암 예후 예측용 조성물 및 방법
CA3043489A1 (en) 2016-11-21 2018-05-24 Nanostring Technologies, Inc. Chemical compositions and methods of using same
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
US11978535B2 (en) * 2017-02-01 2024-05-07 The Translational Genomics Research Institute Methods of detecting somatic and germline variants in impure tumors
CA3078158A1 (en) 2017-10-06 2019-04-11 Cartana Ab Rna templated ligation
KR102071491B1 (ko) * 2017-11-10 2020-01-30 주식회사 디시젠 차세대 염기서열분석을 이용한 기계학습 기반 유방암 예후 예측 방법 및 예측 시스템
EP3794146A1 (en) 2018-05-14 2021-03-24 Nanostring Technologies, Inc. Chemical compositions and methods of using same
EP3877549A1 (en) * 2018-11-05 2021-09-15 BioNTech Diagnostics GmbH Predictive methods in breast cancer
CA3139791A1 (en) 2019-05-31 2020-12-03 10X Genomics, Inc. Method of detecting target nucleic acid molecules
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
WO2023117807A1 (en) * 2021-12-20 2023-06-29 Reveal Genomics S.L Development and validation of an in vitro method for the prognosis of patients suffering from her2-positive breast cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
DE69217497T2 (de) 1991-09-18 1997-06-12 Affymax Tech Nv Verfahren zur synthese der verschiedenen sammlungen von oligomeren
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69233501T2 (de) 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6033860A (en) 1997-10-31 2000-03-07 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US20020168639A1 (en) * 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
ES2690168T3 (es) 2003-06-24 2018-11-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
US20050071087A1 (en) * 2003-09-29 2005-03-31 Anderson Glenda G. Systems and methods for detecting biological features
CA2574447A1 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
CN101061480A (zh) * 2004-09-22 2007-10-24 三路影像公司 用来分析和优化用于癌症诊断的标记候选物的方法和计算机程序产品
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
ES2374788T3 (es) 2005-12-23 2012-02-22 Nanostring Technologies, Inc. Nanoinformadores y métodos para su producción y uso.
AU2006330834B2 (en) 2005-12-23 2013-09-12 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
JP2010538609A (ja) * 2007-09-06 2010-12-16 バイオセラノスティクス,インコーポレイティド 腫瘍グレード分類と癌の予後診断
WO2009158143A1 (en) 2008-05-30 2009-12-30 The University Of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
ES2614810T3 (es) 2008-08-14 2017-06-02 Nanostring Technologies, Inc Nanoindicadores estables
MX2012011167A (es) * 2010-03-31 2013-02-07 Sividon Diagnostics Gmbh Metodo para prediccion de recurrencia de cancer de mama bajo tratamiento endocrino.

Also Published As

Publication number Publication date
US20200332368A1 (en) 2020-10-22
US20130337444A1 (en) 2013-12-19
EP2852689A4 (en) 2016-05-11
EP2852689B1 (en) 2019-12-11
JP2015518724A (ja) 2015-07-06
WO2013177245A3 (en) 2015-01-29
JP6325530B2 (ja) 2018-05-16
IL235795A0 (en) 2015-01-29
CA2874492A1 (en) 2013-11-28
EP2852689A2 (en) 2015-04-01
CN111500718A (zh) 2020-08-07
AU2013266419A1 (en) 2014-12-11
WO2013177245A2 (en) 2013-11-28
CN104704128A (zh) 2015-06-10
MX2014014275A (es) 2015-07-06
AU2013266419B2 (en) 2018-09-27
BR112014029300A2 (pt) 2017-07-25
US20230272476A1 (en) 2023-08-31
MX369628B (es) 2019-11-14
CA2874492C (en) 2021-10-19
IL235795B (en) 2020-02-27
ES2763931T3 (es) 2020-06-01

Similar Documents

Publication Publication Date Title
IN2014MN02418A (ko)
CY1114993T1 (el) Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
NZ599194A (en) Methods to predict clinical outcome of cancer
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
MX357429B (es) Predictores para el tratamiento del cáncer.
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
NZ621638A (en) Dna methylation in colorectal and breast cancer diagnostic methods
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
Montserrat et al. Present and future of personalized medicine in CLL
RU2010149541A (ru) Способ прогнозирования развития метаболического синдрома у пациента с абдоминальным ожирением
MX2013013153A (es) La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.
Eapen Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant?
Cui et al. DIFFERENTIALLY EXPRESSED MIRNAS AND THEIR SURVIVAL PREDICTION IN THE HIGH GRADE SEROUS AND CLEAR CELL OVARIAN CARCINOMA: IGCS-0043 06. Ovarian Cancer
UA108260U (uk) Спосіб прогнозування розвитку остеопорозу
WO2011133500A3 (en) Detection and analysis of epigenetic and genetic changes in tumor tissue
UA95616U (uk) Спосіб прогнозування зрощення перелому
Salmoiraghi et al. Next Generation Sequencing (NGS) of TP53 Gene Allows to Identify a Very High Risk Group of Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Patients
Brennan Quantifying Biomarker Risks and Benefits
Gonzalez-Angulo Putting Genomics into Clinical Practice
Ellis Whole Genome Sequencing for Luminal-Type Breast Cancer